J&J Pushes Pa. Justices To Limit Risperdal Claims Window

By Matt Fair (January 30, 2019, 7:12 PM EST) -- In an appeal affecting thousands of cases pending in Philadelphia, a Johnson & Johnson unit has urged the Pennsylvania Supreme Court to find that a two-year window for claims of breast growth allegedly linked to the antipsychotic medication Risperdal should have started to run when additional warnings about the drug's risk were added in October 2006....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as